InvestorsHub Logo
Followers 82
Posts 3648
Boards Moderated 0
Alias Born 02/15/2010

Re: McMagyar post# 65970

Saturday, 06/25/2016 8:00:28 PM

Saturday, June 25, 2016 8:00:28 PM

Post# of 458336
Good post -

Prana's drug was a good candidate for failure. It was not reversing the effects of Alzheimer's like A2-73, just possibly slowing progression.

Macfarlane's enthusiasm during the Prana trial was directed at one patient. Currently, his enthusiasm is for the entire A2-73 trial.

Macfarlane said that the drug seems to have slowed the progression of the disease by about 30 percent in patients with mild Alzheimer’s compared to placebo.

https://www.equities.com/news/prana-biotechnology-pran-continues-upward-on-alzheimer-s-disease-drug-news

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News